Home Online Features FDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease
FDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease
Hand-out
Press Releases
January 26, 2025

FDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease

By Eisai Inc.

Once every four weeks maintenance dosing may be easier for patients and care partners to continue treatment

bradford

The Bradford Era

email
Local & Social